Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
about
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryAntineoplastic agents and thrombotic microangiopathy.Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adultsIncidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant.The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case ReportVariable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantationTherapeutic apheresis for patients with cancer.Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
P2860
Q26992169-60F9E50F-BF09-42E9-AE9C-AF5E193B9D68Q30251919-CD39ABD8-89C7-46A1-8F84-B6815CF9A3E4Q33415603-8A6700A1-3B55-453D-817A-8E626FB86E89Q33421514-973E02E9-FA1B-40A7-8592-20D19C9A5029Q33424153-D9D66378-7BB1-467E-9C25-053847D8AD74Q33424311-88B2CDF7-9A60-478C-BE9E-97E468F70C7CQ33424660-EB3672B7-CAA7-4398-8032-7F255A6CA57FQ33426602-F35939BB-54A7-4B04-BF08-584BFAA1B9FCQ33573529-320DE82A-8892-4023-990F-73D3B41A5AC8Q38287610-5FA71997-62DD-411D-98BE-E04197D98DFEQ48346280-656C5CB9-E89B-4746-BA0B-C346D079AAAEQ52875784-7CA790DB-BD97-4ACE-A7D2-90FE7D3F7B3F
P2860
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@ast
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@en
type
label
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@ast
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@en
prefLabel
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@ast
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@en
P2093
P2860
P356
P1476
Risk factors for thrombotic mi ...... rolimus plus MTX or sirolimus.
@en
P2093
D Caballero
E Pérez-López
J A Pérez-Simón
J Labrador
J R González-Porras
L López-Corral
M C Del Cañizo
M Cabrero-Calvo
P2860
P2888
P304
P356
10.1038/BMT.2014.17
P407
P577
2014-02-24T00:00:00Z
P5875
P6179
1019654075